{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:19:49Z","timestamp":1699402789761},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>In addition to standard postmarketing drug safety monitoring, Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) requires the US Food and Drug Administration (FDA) to conduct a summary analysis of adverse event reports to identify risks of a drug or biologic product 18 months after product approval, or after 10,000 patients have used the product, whichever is later. We assessed the extent to which these analyses identified new safety signals and resultant safety\u2010related label changes. Among 458 newly approved products, 300 were the subjects of a scheduled analysis; a new safety signal that resulted in a safety\u2010related label change was found for 11 of these products. Less than 2% of 713 safety\u2010related label changes were based on the scheduled analyses. Our study suggests that the safety summary analyses provide only marginal value over other pharmacovigilance activities.<\/jats:p>","DOI":"10.1002\/cpt.346","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T11:44:29Z","timestamp":1454931869000},"page":"102-108","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions"],"prefix":"10.1111","volume":"100","author":[{"given":"S","family":"Sekine","sequence":"first","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"},{"name":"Office of International Programs Pharmaceuticals and Medical Devices Agency Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EE","family":"Pinnow","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Wu","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Kurtzig","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hall","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GJ","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3395"},{"key":"#cr-split#-e_1_2_9_2_1.1","unstructured":"Food and Drug Administration Amendments Act of 2007 Title IX Section 915 (505(r)(2)"},{"key":"#cr-split#-e_1_2_9_2_1.2","unstructured":"(D) Federal Food Drug and Cosmetic Act(2007). U.S. Government Publishing Office Website. <http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW\u2010110publ85\/pdf\/PLAW\u2010110publ85.pdf>. Accessed 24 September 2015."},{"key":"e_1_2_9_3_1","unstructured":"Guidance for Industry: Expedited Programs for Serious Conditions \u2013 Drugs and Biologics. US Food and Drug Administration Website. <http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM358301.pdf>. Accessed 24 September 2015."},{"key":"e_1_2_9_4_1","unstructured":"Orphan Drug Act. US Food and Drug Administration Website. <http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm364750.htm>. Accessed 24 September 2015."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3160"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0012-y"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0706341"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0122"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2007.10.007"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1774"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-5907.2011.00544.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc086158"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.13"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1317-3"},{"key":"e_1_2_9_15_1","unstructured":"ICH guideline: E2C(R2) Periodic Benefit\u2010Risk Evaluation Report. ICH Website. <http:\/\/www.ich.org\/products\/guidelines\/efficacy\/article\/efficacy\u2010guidelines.html>. Accessed 24 September 2015."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.308"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599100-000000000-00000"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.23.3036"},{"key":"e_1_2_9_19_1","unstructured":"Accelerated Approval of New Drugs for Serious or Life\u2010Threatening Illnesses.Code of Federal RegulationsTitle 21 Part 314 Subpart H. <http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8>. Accessed 24 September 2015."},{"key":"e_1_2_9_20_1","unstructured":"Drug Safety Labeling changes. US Food and Drug Administration Website. <http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/Safety\u2010RelatedDrugLabelingChanges\/default.htm>. Accessed 24 September 2015."},{"key":"e_1_2_9_21_1","volume-title":"SAS 9.3 Procedures Guide","author":"SAS Institute","year":"2011"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.346","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:29:00Z","timestamp":1699363740000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/cpt.346"],"URL":"https:\/\/doi.org\/10.1002\/cpt.346","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}